Atrial Fibrillation Clinical Trial
Official title:
A Randomized Controlled Study of Ablation Pursuing Atrial Fibrillation Termination as a Procedural Endpoint Versus Prespecified Ablation Strategy Followed by Cardioversion in Patients With Persistent Atrial Fibrillation
Verified date | June 2023 |
Source | Shanghai Chest Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a prospective, randomized, multi-center trial that aims to investigate whether termination of atrial fibrillation can be used as an ablation endpoint for persistent atrial fibrillation (PersAF). Eligible patients who provided consent were randomly assigned to one of two groups: the AF-termination group (whose ablation endpoint was the pursuit of AF-termination) or the prespecified-ablation group (whose ablation endpoint was prespecified ablation followed by electrical cardioversion).
Status | Not yet recruiting |
Enrollment | 544 |
Est. completion date | December 31, 2025 |
Est. primary completion date | December 31, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility | Inclusion Criteria: 1. . Age 18-80 years old. 2. . Patients undergoing a first-time ablation procedure for PersAF. 3. . Diagnosed as persistent AF according to the latest clinical guidelines. 4. . Ineffective or intolerable to =1 anti-arrhythmia drug treatment. 5. . Patients must be able and willing to provide written informed consent to participate in this study. Exclusion Criteria: 1. . Uncontrolled congestive heart failure; 2. . History of severe valve disease and/or prosthetic valve replacement; 3. . Myocardial infarction or stroke within 6 months; 4. . Severe congenital heart disease; 5. . EF <35%; 6. . Contrast agent allergy; 7. . The use of anticoagulant drugs is contraindicated; 8. . Severe lung disease; 9. . Left atrial thrombus confirmed by preoperative esophageal ultrasound; 10. . Contraindications for cardiac catheterization; 11. . Prior left atrial ablation (surgical or catheter); 12. . Have performed any cardiac surgery within 2 months; 13. . Poor general health; 14. . Life expectancy < 12 months. |
Country | Name | City | State |
---|---|---|---|
China | Mu Qin | Shanghai | |
China | Shanghai Chest Hospital | Shanghai |
Lead Sponsor | Collaborator |
---|---|
Shanghai Chest Hospital |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | freedom from any documented atrial arrhythmia - atrial fibrillation (AF), atrial tachycardia (AT), or atrial flutter (AFL) - of more than 30 seconds, excluding the initial 3 months blanking period | All patients included in the study had no incidence of Atrial fibrillation (AF), atrial tachycardia (AT) or Atrial flutter (AFL) at 12 months after ablation, excluding the initial 3-month blank period | Time Frame: 12 months | |
Secondary | freedom from AF/AT after a single procedure without AADs (excludes the blanking period) | All patients included in the study had no incidence of AF/AT after a single procedure without AADs at 12 months after ablation excluding the initial 3-month blank period | Time Frame: 12 months | |
Secondary | freedom from AF/AT after a single procedure with or without anti-arrhythmic medications (excludes the blanking period) | All patients included in the study had no incidence of freedom from AF/AT after a single procedure with or without anti-arrhythmic medications at 12 months after ablation excluding the initial 3-month blank period | Time Frame: 12 months | |
Secondary | any documented AF episode lasting more than 30 seconds after the blanking period without anti-arrhythmic drugs (AADs) treatment | All patients included in the study had no incidence of any documented AF episode lasting more than 30 seconds after the blanking period without anti-arrhythmic drugs (AADs) treatment at 12 months after ablation, excluding the initial 3-month blank period | Time Frame: 12 months | |
Secondary | freedom from any AT episodes lasting more than 30 seconds after the blanking period without AADs after a single procedure | All patients included in the study had no incidence of any AT episodes lasting more than 30 seconds after the blanking period without anti-arrhythmic drugs (AADs) treatment at 12 months after ablation, excluding the initial 3-month blank period | Time Frame: 12 months | |
Secondary | procedural details | All patients' procedural details: including procedure time, mapping time, fluoroscopy time, ablation time. | Time Frame: 12 months | |
Secondary | incidence of periprocedural adverse events | All patients' periprocedural adverse events including:ascular- significant groin,haematoma, pseudoaneurysm, AV fistula,Cardiac perforation,Pericardial effusion/ tamponade,Pericarditis,Pneumothorax/ haemothorax,Phrenic nerve injury,Periprocedural cerebrovascular accident - including air embolism,Esophageal injury - perforation / atrio-esophageal fistula,Pulmonary vein stenosis,Major bleeding event -including retroperitoneal bleeding,Heart block,Death | Time Frame: 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05654272 -
Development of CIRC Technologies
|
||
Terminated |
NCT04115735 -
His Bundle Recording From Subclavian Vein
|
||
Completed |
NCT04571385 -
A Study Evaluating the Efficacy and Safety of AP30663 for Cardioversion in Participants With Atrial Fibrillation (AF)
|
Phase 2 | |
Completed |
NCT05366803 -
Women's Health Initiative Silent Atrial Fibrillation Recording Study
|
N/A | |
Completed |
NCT02864758 -
Benefit-Risk Of Arterial THrombotic prEvention With Rivaroxaban for Atrial Fibrillation in France
|
||
Recruiting |
NCT05442203 -
Electrocardiogram-based Artificial Intelligence-assisted Detection of Heart Disease
|
N/A | |
Completed |
NCT05599308 -
Evaluation of Blood Pressure Monitor With AFib Screening Feature
|
N/A | |
Completed |
NCT03790917 -
Assessment of Adherence to New Oral anTicoagulants in Atrial Fibrillation patiEnts Within the Outpatient registrY
|
||
Enrolling by invitation |
NCT05890274 -
Atrial Fibrillation (AF) and Electrocardiogram (EKG) Interpretation Project ECHO
|
N/A | |
Recruiting |
NCT05266144 -
Atrial Fibrillation Patients Treated With Catheter Ablation
|
||
Recruiting |
NCT05316870 -
Construction and Effect Evaluation of Anticoagulation Management Model in Atrial Fibrillation
|
N/A | |
Not yet recruiting |
NCT06023784 -
The Impact of LBBAP vs RVP on the Incidence of New-onset Atrial Fibrillation in Patients With Atrioventricular Block
|
N/A | |
Recruiting |
NCT05572814 -
Transform: Teaching, Technology, and Teams
|
N/A | |
Recruiting |
NCT04092985 -
Smart Watch iECG for the Detection of Cardiac Arrhythmias
|
||
Completed |
NCT04087122 -
Evaluate the Efficiency Impact of Conducting Active Temperature Management During Cardiac Cryoablation Procedures
|
N/A | |
Completed |
NCT06283654 -
Relieving the Emergency Department by Using a 1-lead ECG Device for Atrial Fibrillation Patients After Pulmonary Vein Isolation
|
||
Recruiting |
NCT05416086 -
iCLAS™ Cryoablation System Post-Market Clinical Follow-up (PMCF) Study
|
N/A | |
Completed |
NCT05067114 -
Solutions for Atrial Fibrillation Edvocacy (SAFE)
|
||
Completed |
NCT04546763 -
Study Watch AF Detection At Home
|
||
Completed |
NCT03761394 -
Pulsewatch: Smartwatch Monitoring for Atrial Fibrillation After Stroke
|
N/A |